Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BBP-711 · 1 trial · 1 indication
Incidence of Adverse Events (AEs)
| Arm | Type | Description |
|---|---|---|
| BBP-711 for SAD | EXPERIMENTAL | A single dose of BBP-711 will be administered orally. |
| Placebo for SAD | PLACEBO_COMPARATOR | A single dose of matching placebo will be administered orally. |
| BBP-711 for MAD | EXPERIMENTAL | A dose of BBP-711 will be administered orally for multiple days. |
| Placebo for MAD | PLACEBO_COMPARATOR | A dose of matching placebo will be administered orally for multiple days. |
| BBP-711 for SAD Food Effect | EXPERIMENTAL | A single dose of BBP-711 will be administered orally. |
| Placebo for SAD Food Effect | PLACEBO_COMPARATOR | A single dose of matching placebo will be administered orally. |
| Name | Type | Description |
|---|---|---|
| BBP-711 | DRUG | BBP-711, oral suspension |
| Placebo | DRUG | Placebo matching BBP-711 |
Inclusion Criteria: * Adult male or female who is 18 to 65 years old, * Weight \>50 kg and ≤110 kg at Screening * Body mass index (BMI) 20 to 32 kg/m2, inclusive, at Screening * In generally good health * Nonsmoker, or not using tobacco or nicotine-containing products for at least 6 months Exclusi...
BBP-711 is an investigational small molecule being studied in healthy adult volunteers. It is currently in Phase 1 clinical development, and the completed trial evaluated its safety and tolerability in healthy participants. BBP-711 is not approved for any medical condition and remains in early-stage clinical testing.
BBP-711 is being developed by BridgeBio Pharma, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol BBIO. The company is conducting clinical research on this investigational small molecule in healthy volunteers.
BBP-711 is in Phase 1 clinical development. The single completed Phase 1 trial enrolled 92 healthy adult volunteers in the United States. As an investigational drug, BBP-711 has not been approved by regulatory authorities and is still in early-stage clinical testing.
BBP-711 has one completed Phase 1 clinical trial registered as NCT04876924, titled "A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers." This randomized, double-blind, placebo-controlled study enrolled 92 healthy participants aged 18 years and older in the United States.
Yes, BBP-711 is also known as ORF-229. The clinical trial NCT04876924, which studied BBP-711 in healthy adult volunteers, refers to the drug as BBP-711 (ORF-229), confirming that these names refer to the same investigational compound.